- Home
- LUCD vs PLX Comparison
LUCD vs PLX Comparison
Compare LUCD & PLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LUCD
- PLX
- Stock Information
- Founded
- LUCD 2018
- PLX 1993
- Country
- LUCD United States
- PLX United States
- Employees
- LUCD 70
- PLX N/A
- Industry
- LUCD Biotechnology: Electromedical & Electrotherapeutic Apparatus
- PLX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- LUCD Health Care
- PLX Health Care
- Exchange
- LUCD Nasdaq
- PLX Nasdaq
- Market Cap
- LUCD 135.6M
- PLX 160.2M
- IPO Year
- LUCD 2021
- PLX 1998
- Fundamental
- Price
- LUCD $1.19
- PLX $2.87
- Analyst Decision
- LUCD Strong Buy
- PLX Strong Buy
- Analyst Count
- LUCD 4
- PLX 1
- Target Price
- LUCD $3.88
- PLX $15.00
- AVG Volume (30 Days)
- LUCD 1.3M
- PLX 753.1K
- Earning Date
- LUCD 05-14-2025
- PLX 05-09-2025
- Dividend Yield
- LUCD N/A
- PLX N/A
- EPS Growth
- LUCD N/A
- PLX N/A
- EPS
- LUCD N/A
- PLX 0.04
- Revenue
- LUCD $4,346,000.00
- PLX $53,399,000.00
- Revenue This Year
- LUCD $107.75
- PLX $65.02
- Revenue Next Year
- LUCD $231.37
- PLX $57.34
- P/E Ratio
- LUCD N/A
- PLX $79.67
- Revenue Growth
- LUCD 79.00
- PLX N/A
- 52 Week Low
- LUCD $0.63
- PLX $0.82
- 52 Week High
- LUCD $1.80
- PLX $3.10
- Technical
- Relative Strength Index (RSI)
- LUCD 40.89
- PLX 56.85
- Support Level
- LUCD $1.19
- PLX $2.70
- Resistance Level
- LUCD $1.24
- PLX $2.64
- Average True Range (ATR)
- LUCD 0.07
- PLX 0.17
- MACD
- LUCD -0.00
- PLX -0.01
- Stochastic Oscillator
- LUCD 10.53
- PLX 61.67
About LUCD Lucid Diagnostics Inc.
Lucid Diagnostics Inc is a commercial-stage medical diagnostics technology company focused on the millions of patients with gastroesophageal reflux disease (GERD), also known as chronic heartburn, acid reflux, or simply reflux, who are at risk of developing esophageal precancer and cancer, specifically lethal esophageal adenocarcinoma. Its products include EsoCheck and EsoGuard.
About PLX Protalix BioTherapeutics Inc. (DE)
Protalix BioTherapeutics Inc is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx protein expression system or ProCellEx. It has developed taliglucerase alfa for the treatment of Gaucher disease. The company's products also treat diseases like Fabry disease and cystic fibrosis. The company's primary sources of revenue include its sales of BioManguinhos alfataliglicerase in Brazil and of drug substances to Pfizer under its Amended Pfizer Agreement. The company's pipeline consists of ELFABRIO, Uricase, and Long Acting DNase I.